Top

International Journal of Colorectal Disease

Published in:

01-07-2004 | Review

Medical approaches and future options in chronic active ulcerative colitis

Authors: J. T. Siveke, C. Folwaczny

Published in: International Journal of Colorectal Disease | Issue 4/2004

Abstract

Background

Immunosuppressive therapy employing purine analogues is the therapeutic mainstay in patients with chronic active ulcerative colitis. However, despite therapeutic optimization according to thiopurine-methyltransferase activity or red blood cell 6-thioguanine levels, a substantial proportion of patients does not tolerate azathioprine or 6-mercaptopurine or relapses during this treatment. In the latter multiple therapeutic regimens comprising 6-thioguanine, cyclosporin or tacrolimus, methotrexate, cyclophosphamide, infliximab, interferons, heparin, leukocyte apheresis, and various other regimens might be considered aiming at long-term remission. Many of these treatment forms have only been evaluated in small mostly uncontrolled trials.

Objective

In this review existing treatment modalities and future options for patients with chronic active ulcerative colitis will be discussed focusing on immunomodulating approaches.

Nielsen OH, Vainer B, Rask-Madsen J (2001) Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 15:1699–1708CrossRefPubMed

Kamm MA (2002) Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 16:21–24CrossRefPubMed

Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50:485–489CrossRefPubMed

Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–1145CrossRefPubMed

Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE (1992) Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305:20–22PubMed

Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo RM, Pol A, Lhermitte M, Lafitte JJ, Libersa C, Broly F (1998) Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125:879–887PubMed

Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118:1025–1030PubMed

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122:904–915PubMed

Corominas H, Domenech M, Gonzalez D, Diaz C, Roca M, Garcia-Gonzalez MA, Pena S, Baiget M (2000) Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 95:2313–2317CrossRefPubMed

10.

Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RN (2000) Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 30:409–413CrossRefPubMed

11.

Schwab M, Klotz U (2001) Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 40:723–751PubMed

12.

Regueiro M, Mardini H (2002) Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn’s disease. J Clin Gastroenterol 35:240–244CrossRefPubMed

13.

Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum M, Zanger UM, Kaskas BA (2002) Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12:429–436CrossRefPubMed

14.

Paerregaard A, Schmiegelow K (2002) Monitoring azathioprine metabolite levels and thiopurine methyl transferase (TPMT) activity in children with inflammatory bowel disease. Scand J Gastroenterol 37:371–372CrossRefPubMed

15.

Lennard L (2002) TPMT in the treatment of Crohn’s disease with azathioprine. Gut 51:143–146CrossRefPubMed

16.

McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR (2002) Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 122:838–839PubMed

17.

Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M (2001) Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn’s disease using phenotyping only. Gastroenterology 121:498–499PubMed

18.

Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705–713PubMed

19.

Cuffari C, Hunt S, Bayless T (2001) Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48:642–646CrossRefPubMed

20.

Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ (2001) Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49:665–670CrossRefPubMed

21.

Snow JL, Gibson LE (1995) The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 131:193–197CrossRefPubMed

22.

Colonna T, Korelitz BI (1994) The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn’s disease. Am J Gastroenterol 89:362–366PubMed

23.

Campbell S, Ghosh S (2001) Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 13:1073–1076CrossRefPubMed

24.

Decaux G, Prospert F, Horsmans Y, Desager JP (2000) Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 135:256–262CrossRefPubMed

25.

Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA (2001) An open-label pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 7:181–189CrossRefPubMed

26.

Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF (2003) 6-thioguanine—efficacy and safety in chronic active Crohn’s disease. Aliment Pharmacol Ther 17:503–508CrossRefPubMed

27.

Rulyak SJ, Saunders MD, Lee SD (2003) Hepatotoxicity associated with 6-thioguanine therapy for Crohn’s disease. J Clin Gastroenterol 36:234–237CrossRefPubMed

28.

Cohen RD, Stein R, Hanauer SB (1999) Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 94:1587–1592CrossRefPubMed

29.

Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–1845CrossRefPubMed

30.

Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R (1998) Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 4:276–279PubMed

31.

Rosselli M, Casa A, Oliva L, Orlando A, Cottone M (1996) Treatment of acute a steroid-resistant ulcerative colitis with continuous venous infusion of cyclosporine (in Italian). Recenti Prog Med 87:416–421PubMed

32.

Van Assche G, D’Haens G, Noman M, Hiele M, Asnong K, Aerden I (2002) Randomized double blind comparison of 4 gm/kg versus 2 mg/kg IV cyclosporine in severe ulcerative colitis. Gastroenterology 122:A81

33.

D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P (2001) Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120:1323–1329

34.

Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR (1994) A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106:1429–1435PubMed

35.

Stack WA, Long RG, Hawkey CJ (1998) Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 12:973–978CrossRefPubMed

36.

Stange EF (2001) Guidelines of the DGVS. Fulminant process. German Society of Digestive and Metabolic Diseases (in German). Z Gastroenterol 39:39–42CrossRefPubMed

37.

Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF (1998) Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 93:1860–1866CrossRefPubMed

38.

Matsuhashi N, Nakajima A, Watanabe K, Komeno Y, Suzuki A, Ohnishi S, Omata M, Kondo K, Usui Y, Iwadare JI, Watanabe T, Nagawa H, Muto T (2000) Tacrolimus in corticosteroid-resistant ulcerative colitis. J Gastroenterol 35:635–640

39.

Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF (2002) Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 8:317–324PubMed

40.

Fraser AG (2003) Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 15:225–231CrossRefPubMed

41.

Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR (1989) Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110:353–356PubMed

42.

Baron TH, Truss CD, Elson CO (1993) Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 38:1851–1856PubMed

43.

Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Bardan E, Villa Y, Gilat T (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110:1416–1421PubMed

44.

Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ (1999) A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 13:1597–1604CrossRefPubMed

45.

Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R (2000) 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 12:1227–1233PubMed

46.

Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P (2002) Azathioprine or methotrexate in the treatment of patients with steroid- dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 16:1751–1759CrossRefPubMed

47.

Kozarek RA (1996) Methotrexate and ulcerative colitis: wrong drug? Wrong dose? Or wrong disease? Gastroenterology 110:1652–1656PubMed

48.

Siveke JT, Folwaczny C (2003) Methotrexate in ulcerative colitis. Aliment Pharmacol Ther 17:479–480CrossRefPubMed

49.

Fraser AG, Morton D, McGovern D, Travis S, Jewell DP (2002) The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 16:693–697CrossRefPubMed

50.

van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524CrossRefPubMed

51.

Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M (2003) Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 52:377–382CrossRefPubMed

52.

Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, Galle PR, Neurath MF (2000) Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 95:1201–1207CrossRefPubMed

53.

Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, Loeschke K, Stange EF (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176CrossRefPubMed

54.

Chey WY, Hussain A, Ryan C, Potter GD, Shah A (2001) Infliximab for refractory ulcerative colitis. Am J Gastroenterol 96:2373–2381PubMed

55.

Chey WY (2001) Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 7 [Suppl 1]:S30–S33

56.

Kaser A, Mairinger T, Vogel W, Tilg H (2001) Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 113:930–933PubMed

57.

Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M (2002) Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 34:626–630CrossRefPubMed

58.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK (2001) Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7:83–88PubMed

59.

Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97:2577–2584CrossRefPubMed

60.

Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52:998–1002CrossRefPubMed

61.

Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM (1997) Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 11:1031–1035CrossRefPubMed

62.

Pena AS (2001) What have we learned from the biological therapies in ulcerative colitis? Am J Gastroenterol 96:1681–1684CrossRefPubMed

63.

van Assche G, Rutgeerts P (2002) Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 8:291–300PubMed

64.

Lofberg R, Neurath MF, Ost A, Pettersson S (2002) Topical NFκB p65 antisense oligonucleotides in patients with active distal colonic IBD. A randomized, controlled pilot trial. Gastroenterology 122:A60

65.

Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, Munkholm P (2001) An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 96:1807–1815CrossRefPubMed

66.

Ruther U, Nunnensiek C, Muller HA, Bader H, May U, Jipp P (1998) Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn’s disease). Hepatogastroenterology 45:691–699PubMed

67.

Sumer N, Palabiyikoglu M (1995) Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 7:597–602PubMed

68.

Hadziselimovic F, Schaub U, Emmons LR (1995) Interferon alpha-2A (roferon) as a treatment of inflammatory bowel disease in children and adolescents. Adv Exp Med Biol 6:1323–1326

69.

Gasche C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M, Wirth HP, Gangl A, Lochs H (1995) Prospective evaluation of interferon-alpha in treatment of chronic active Crohn’s disease. Dig Dis Sci 40:800–804PubMed

70.

Musch E, Andus T, Malek M (2002) Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long- term pilot trial. Aliment Pharmacol Ther 16:1233–1239CrossRefPubMed

71.

Nikolaus S, Rutgeerts P, Fedorak RN, Steinhart H, Wild GE, Theuer D, Schreiber S, Moehrle JJ, Goedkopp RJ (2001) Recombinant human interferon-beta (IFNβ-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology 120:A454

72.

Musch E, Juntgen C, Witzke O, Schwarck H, Huttmann H (1995) Successful therapy of colitis ulcerosa by beta-interferon. Gut 40:A141

73.

Heslop HE, Bianchi AC, Cordingley FT, Turner M, Chandima W, De Mel CP, Hoffbrand AV, Brenner MK (1990) Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 172:1729–1734PubMed

74.

Mahida YR, Wu K, Jewell DP (1989) Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn’s disease. Gut 30:835–838PubMed

75.

Gross V, Andus T, Caesar I, Roth M, Scholmerich J (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 102:514–519

76.

Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272:60–66PubMed

77.

Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S (2003) Natalizumab for active Crohn’s disease. N Engl J Med 348:24–32CrossRefPubMed

78.

Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE (2002) A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 16:699–705CrossRefPubMed

79.

Feagan BG, McDonald JW, Greenberg G, et al. (2000) An ascending dose trial of a humanized A₄B₇ antibody in ulcerative colitis. Gastroenterology 118:A874

80.

Folwaczny C (2002) Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications (in German). Z Gastroenterol 40:991–998CrossRefPubMed

81.

Gaffney PR, O’Leary JJ, Doyle CT, Gaffney A, Hogan J, Smew F, Annis P (1991) Response to heparin in patients with ulcerative colitis. Lancet 337:238–239CrossRefPubMed

82.

Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P (1995) Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 90:220–223PubMed

83.

Evans RC, Wong VS, Morris AI, Rhodes JM (1997) Treatment of corticosteroid-resistant ulcerative colitis with heparin-- a report of 16 cases. Aliment Pharmacol Ther 11:1037–1040CrossRefPubMed

84.

Folwaczny C, Wiebecke B, Loeschke K (1999) Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 94:1551–1555CrossRefPubMed

85.

Dupas JL, Brazier F, Yzet T, Roussel B, Duchmann JC, Iglicki F (1996) Treatment of active Crohn’s disease with heparin. Gastroenterology 110:A900

86.

Brazier F, Yzet T, Boruchowicz A, Colombel JF, Duchmann JC, Dupas JL (1996) Treatment of ulcerative colitis with heparin. Gastroenterology 110:A872

87.

Evans RC, Rhodes JM (1995) Heparin, used i. v. and with sulphasalazine, appears to be effective in the treatment of refractory U.C., and warrants larger controlled trials. Gut 37 [Suppl 2]:A49

88.

Folwaczny C, Spannagl M, Wiebecke W, Jochum M, Heldwein W, Loeschke K (1996) Heparin in the treatment of highly active inflammatory bowel disease (IBD). Gastroenterology 110:A908

89.

Iglicki F, Dupas JL (1996) Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel disease. Gastroenterology 110:A872

90.

Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R (1999) Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 13:1323–1328CrossRefPubMed

91.

Vrij AA, Jansen JM, Schoon EJ, de Bruine A, Hemker HC, Stockbrugger RW (2001) Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol [Suppl 234]:41–47

92.

Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z (2001) Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 46:2239–2244CrossRefPubMed

93.

Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW (2000) Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 14:1015–1022CrossRefPubMed

94.

Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, Fernandez-Banares F, Feu F, Gassull MA, Pique JM (2000) Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 119:903–908PubMed

95.

Folwaczny C (2001) Heparin therapy for ulcerative colitis. Gastroenterology 120:1307, discussion 1307–1308PubMed

96.

Korzenik J, Miner Jr P, Stanton D, Isaacs K, Zimmermann E, Riff D, De Villiers W, Venuti R (2003) Multicenter, randomized, double-blind placebo-controlled trial of Deligoparin (ultra low molecular weight heparin) for active ulcerative colitis. Gastroenterology 124:A67

97.

Bloom S, Külerich s, Lassen MR, O’Morain C, Forbes A, Orm S (2003) Randomized trial of tinzaparin, a low molecular weight heparin (LMWH), versus placebo in the treatment of mild to moderately active ulcerative colitis. Gastroenterology 124:A67

98.

De Bievre M, Vrji AA, Oberndorff-Klein AH, Hemker HC, Stockbrugger RW (2003) A randomized placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Gastroenterology 124:A68

99.

Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, Izawa H, Yamamura M, Amano K, Satomi M, Shimoyama T (1997) Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1:207–211PubMed

100.

Kohgo Y, Hibi H, Chiba T, Shimoyama T, Muto T, Yamamura K, Popovsky MA (2002) Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial. Ther Apher 6:255–260CrossRefPubMed

101.

Kondo K, Shinoda T, Yoshimoto H, Takazoe M, Hamada T (2001) Effective maintenance leukocytapheresis for patients with steroid dependent or resistant ulcerative colitis. Ther Apher 5:462–465CrossRefPubMed

102.

Sawada K, Kusugam K, Suzuki Y, Bamba T, Munakata A, Hibi T, Fukuda Y, Shimoyama T (2003) Multicenter randomized double blind controlled trial for ulcerative colitis therapy with leukocytapheresis. Gastroenterology 124:A67

103.

Folwaczny C, Fricke H, Endres S, Hartmann G, Jochum M, Loeschke K (1997) Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study. Am J Gastroenterol 92:911–912PubMed

104.

Marshall JK, Irvine EJ (1997) Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40:775–781PubMed

105.

Danielsson A, Hellers G, Lyrenas E, Lofberg R, Nilsson A, Olsson O, Olsson SA, Persson T, Salde L, Naesdal J, et al. (1987) A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 22:987–992PubMed

106.

Danielsson A, Lofberg R, Persson T, Salde L, Schioler R, Suhr O, Willen R (1992) A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 27:9–12PubMed

107.

Lofberg R, Ostergaard Thomsen O, Langholz E, Schioler R, Danielsson A, Suhr O, Graffner H, Pahlman L, Matzen P, Moller-Petersen JF, et al. (1994) Budesonide versus prednisolone retention enemas in active distal. Aliment Pharmacol Ther 8:623–629PubMed

108.

Folwaczny C (1998) Alternative therapeutic approaches in IBD. Proceedings of the Falk Symposium 105:317–327

109.

Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, Harig JM, Keshavarzian A, Robinson M, Sellin JH, Weinberg D, Vidican DE, Flemal KL, Rademaker AW (1997) Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 40:485–491PubMed

110.

Steinhart AH, Hiruki T, Brzezinski A, Baker JP (1996) Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 10:729–736CrossRefPubMed

111.

Bjorck S, Dahlstrom A, Ahlman H (2002) Treatment of distal colitis with local anaesthetic agents. Pharmacol Toxicol 90:173–180CrossRefPubMed

112.

Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, et al. (1994) Transdermal nicotine for active ulcerative colitis. N Engl J Med 330:856–857CrossRefPubMed

113.

Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD (1997) Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126:364–371PubMed

114.

Thomas AG, Rhodes J, Ragunath K, Mani V, Williams GT, Newcombe RG, Russell MA, Feyerabend C (1996) Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 8:769–776PubMed

115.

Guslandi M, Tittobello A (1998) Outcome of ulcerative colitis after treatment with transdermal nicotine. Eur J Gastroenterol Hepatol 10:513–515PubMed

116.

Thomas AG, Rhodes J, Mani V, Williams GT, Newcombe RG, Russell MA, Feyerabend C (1995) Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 332:988–992

117.

Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD (2001) An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96:3323–3328CrossRefPubMed

Title: Medical approaches and future options in chronic active ulcerative colitis
Authors: J. T. Siveke
C. Folwaczny
Publication date: 01-07-2004
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 4/2004
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-003-0569-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Medical approaches and future options in chronic active ulcerative colitis

Abstract

Background

Objective

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Please log in to get access to this content

Other articles of this Issue 4/2004

Simplified placement and management of cutting setons in the treatment of transsphincteric anal fistula: technical note

Questions on life satisfaction (FLZM) in inflammatory bowel disease

Balloon tamponade to control haemorrhage following transanal rectal surgery

Simplified placement and management of cutting setons in the treatment of transsphincteric anal fistula

Angiostatin inhibits experimental liver fibrosis in mice

Open versus closed day-case haemorrhoidectomy: is there any difference?